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The antibacterial activity of human neutrophil defensin HNP-1 analogs without cysteines has been investi-
gated. A peptide corresponding to the HNP-1 sequence without the six cysteines (HNP-1C) exhibited anti-
bacterial activity toward gram-negative and gram-positive bacteria. Truncated analogs wherein the nine
N-terminal residues of HNP-1 and the remaining three cysteines were deleted (HNP-1C18) or the G was
replaced with A (HNP-1C18A) also exhibited antibacterial activity. Substantial activity was observed for
HNP-1C and HNP-1C18 in the presence of 100 mM NaCl, except in the case of Pseudomonas aeruginosa. The
linear peptides were active in the presence of carbonyl cyanide m-chlorophenylhydrazone (CCCP), indicating
that proton motive force was not essential for killing of bacteria by the peptides. In fact, in the presence of
CCCP, the peptides were active against P. aeruginosa even in the presence of 100 mM NaCl. The antibacterial
activity of HNP-1C, but not that of the shorter, 18-residue peptides, was attenuated in the presence of serum.
The generation of defensins without cysteines would be easier than that of disulfide-linked defensins. Hence,
linear defensins could have potential as therapeutic agents.
Mammalian defensins are a family of cationic antimicrobial
peptides characterized by three disulfide bridges (13, 22, 35).
They are expressed in granulocytes, monocytes, macrophages,
and epithelial cells of the skin, intestines, and other tissues (2,
13, 39). Based on the pattern of disulfide bonding, mammalian
defensins have been classified into  and  families. In another
class named the -defensins, in addition to three disulfide
bridges, the amino- and carboxyl-terminal ends are linked via
an amide bond (13). In humans, -defensins are produced in
neutrophils and Paneth cells of the small intestine, while -de-
fensins are expressed by epithelial cells at various sites (13, 22).
The -defensins have been identified only in primates (13, 19).
The expression of defensins is constitutive as well as induced
by infection and inflammation (13, 22, 23). Defensin biosyn-
thesis and release have been observed to be regulated by mi-
crobial signals, developmental signals, and cytokines (13, 14).
Apart from their role as microbicidal agents, defensins have
also been implicated as effective immune modulators in adap-
tive immunity (11, 54). They have potency to enhance phago-
cytosis, induce the activation and degranulation of mast cells,
and indirectly regulate innate antimicrobial immunity by af-
fecting the production of chemokines such as interleukin-8,
interleukin-10, and tumor necrosis factor from different cells
(3, 24, 53). Studies have also revealed the role of defensins in
adaptive immunity, as reflected by their chemotactic effect on
monocytes, T cells, and immature dendritic cells (5, 32, 35, 43,
48, 54).
Human neutrophil defensins (HNP-1 to HNP-4) are stored
in azurophilic granules of the neutrophil. They are transferred
to phagolysosomes upon phagocytosis to kill the ingested mi-
crobes (14, 15). The crystal structure of HNP-3 reveals a
dimeric structure, with each monomer containing a triple-
stranded -sheet region (16). Nuclear magnetic resonance
studies indicate that HNP-1 also forms dimers or higher-order
aggregates in solution. The three -strands observed in HNP-3
are also present (34, 57). In an effort to determine how essen-
tial the disulfide connections are for antibacterial activity and
structure, we have investigated the antibacterial activity of a
peptide spanning residues A1 to F28 of HNP-1 which does not
have the six cysteines present in HNP-1 (Table 1). We have
also examined the effect of deleting the amino acids AYRIPA
from the N-terminal end of this peptide and the effect of
replacing G with A in the truncated analog (Table 1) on anti-
bacterial activity and structure.
MATERIALS AND METHODS
9-Fluorenylmethoxy carbonyl (F-moc) amino acids were obtained from Nova-
biochem AG (Switzerland) and Advanced Chemtech (Louisville, KY). The F-
moc amide handle crown was from Mimotopes (Australia). 1-N-Phenyl naph-
thylamine (NPN) and carbonyl cyanide m-chlorophenylhydrazone (CCCP) were
obtained from Sigma. All other chemicals used were of the highest grade avail-
able.
Peptide synthesis. Peptides were synthesized using an F-moc amide handle
crown employing F-moc chemistry (1). The synthesized peptides were cleaved
and deprotected by using a mixture containing 82.5% trifluoroacetic acid (TFA),
5% phenol, 5% H2O, 5% thioanisole, and 2.5% ethanedithiol for 12 to 15 h at
room temperature. HNP-1 was synthesized on 4-hydroxymethylphenoxymethyl
resin (Applied Biosystems; 0.9 mmol/g) (28) with the cysteines protected by
acetamidomethyl (46). The removal of acetamidomethyl was effected by Hg(II)
acetate and -mercaptoethanol treatment (28, 46) followed by gel filtration on a
Biogel P-2 column. HNP-1 was then oxidized in 20% dimethyl sulfoxide-water
(42) at a peptide concentration of 0.2 to 0.4 mM. This was followed by gel
filtration with 50% acetonitrile-water containing 0.01% TFA. The peptides were
purified on a Hewlett-Packard 1100 series high-performance liquid chromatog-
raphy instrument with a reversed-phase C4 or C18 Bio-Rad column. The solvents
consisted of 0.1% TFA in H2O as mobile phase A and 0.1% TFA in CH3CN as
mobile phase B. The purified peptides were then characterized by matrix-assisted
laser desorption ionization–time-of-flight mass spectrometry on a Voyager DE
STR mass spectrometer (Applied Biosystems) at the Proteomics Facility of the
Centre for Cellular and Molecular Biology. Stock solutions of HNP-1 analogs
were prepared by dissolving the peptides in water. A stock solution of HNP-1 was
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prepared in 0.01% acetic acid. The concentrations were determined by monitor-
ing the absorbance of tryptophan at 280 nm.
Antibacterial activity. The bacterial strains used were Escherichia coli W
160-37 (47), Staphylococcus aureus (NCTC 8530), and Pseudomonas aeruginosa
(NCTC 6750). Bactericidal activity was determined as follows. Mid-log-phase
bacteria were obtained by growing bacteria in nutrient broth (Bacto; Difco),
washing them twice with 10 mM sodium phosphate buffer (pH 7.4), and then
diluting them in the same buffer to give approximately 106 CFU/ml. A final
volume of 100 l was used in sterile 96-well plates to examine the antibacterial
activity of the peptides. After incubation of the bacteria with different concen-
trations of peptides for 2 h at 37°C, 20 l was plated on nutrient agar plates. The
plates were incubated for 18 h at 37°C, and the colonies formed were counted.
The lowest concentration of peptide at which there was complete killing was
taken as the lethal concentration (LC). In control experiments, cells were incu-
bated with only 0.01% acetic acid (the solvent used to dissolve HNP-1).
Kinetics of bacterial killing. The kinetics of bacterial killing were determined
against gram-negative and gram-positive bacteria. Mid-log-phase bacteria (105
CFU/ml) were incubated with LCs of peptides in 10 mM sodium phosphate
buffer (pH 7.4) in a final volume of 100 l. Aliquots of 20 l were removed at
fixed intervals and plated on nutrient agar plates. The CFU were counted after
an incubation of 16 to 18 h at 37°C. The values mentioned in the results are the
averages of two independent experiments.
Salt sensitivity. Salts (NaCl, 100 mM; MgCl2 and CaCl2, 1 mM and 2 mM)
were added to the incubation buffer to examine the effect of salt on the antibac-
terial activity of the peptides. The effect of salts was examined at the lethal
concentrations of the peptides. E. coli MG1655 (105 CFU/ml) was used to
examine inhibition by MgCl2 and CaCl2. The values determined were the aver-
ages of three independent experiments. The variation was within 5%.
Outer membrane permeabilization assay. The ability of peptides to perme-
abilize the outer membranes of E. coli MG 1655 cells was investigated using an
NPN uptake assay (25, 38). Briefly, cells at an optical density at 600 nm (OD600)
of 0.1 were suspended in 5 mM HEPES (pH 7.4) with 10 M NPN. After 15 min
of incubation, peptides were added, and the fluorescence of NPN was monitored.
The excitation wavelength used was 350 nm, and the emission wavelength was
420 nm. The experiment was carried out at 25°C.
Inner membrane permeabilization assay. The ability of peptides to perme-
abilize the inner membranes of bacteria was studied using E. coli GJ 2455 (lacI
lacZ strain derived from E. coli MG1655 at Centre for Cellular and Molecular
Biology), which constitutively expresses -galactosidase in its cytoplasm. o-Ni-
trophenyl--D-galactopyranoside (ONPG) was used as the substrate for -galac-
tosidase. Late-logarithmic-phase (OD600, 0.5 to 0.6) cells were washed and di-
luted to an OD600 of 0.03 in 10 mM sodium phosphate buffer (pH 7.4), and 0.53
mM ONPG was added. After the addition of different peptide concentrations,
OD measurements were made every 5 min at 550 nm and 420 nm, and absor-
bance calculations [A420  (1.75  A550)] were taken as a measure of the
-galactosidase activity. The production of o-nitrophenol was monitored at 420
nm. The value 1.75 A550 represents the light scattering by cell debris at 420 nm.
Bacterial cells without any peptide were used as a control.
Effect of dissipation of proton motive force on antibacterial activity. The effect
of a loss of proton motive force due to the action of CCCP was examined as
follows. Bacteria were preincubated with 20 M CCCP for 20 min, followed by
the addition of peptides at the LC, with or without NaCl. The effect of incubation
with 50 M CCCP was also examined. CCCP at concentrations of 20 M and 50
M has been used for dissipation of the proton motive force in bacteria (10, 33,
40). The bactericidal activity was determined as described earlier. The values
determined were the averages of three independent experiments. The variation
was within 5%.
Hemolytic activity. Human erythrocytes were used to evaluate the hemolytic
activity of the peptides. Erythrocytes were obtained by centrifuging (800  g)
heparinized blood and then were washed thrice with 5 mM HEPES (pH 7.4)
containing 150 mM NaCl. Aliquots containing 107 red blood cells/ml were incu-
bated in the presence of different peptide concentrations in 0.5-ml Eppendorf
tubes at a final volume of 100 l for 30 min at 37°C with gentle mixing. The tubes
were centrifuged, and the absorbance of the supernatants was measured at 540
nm. Erythrocyte lysis occurring in distilled water was taken as maximal lysis.
Serum sensitivity assay. To study the effect of serum components on the
antimicrobial activity and hemolytic activity of the peptides, serum was isolated
from human blood after the removal of erythrocytes by centrifugation. Total
protein was estimated using the Folin-Ciocalteu-Lowry method (26). For both
antimicrobial activity and hemolytic activity, serum at 1 mg/ml was included in
the buffer and incubated for 15 min before the addition of peptides. Cells with
only serum were used as a control.
Circular dichroism (CD). A JASCO J-715 spectropolarimeter was used to
record the spectra of peptides in water, trifluoroethanol (TFE), and 10 mM
sodium dodecyl sulfate (SDS) at 25°C. A quartz cell with a 1-mm path length was
used. Spectra were recorded in the region from 195 to 250 nm. The concentra-
tions of peptides were 25 M for HNP-1	C, 30 M for HNP-1	C18, and 20 M
for HNP-1	C18A.
RESULTS
Antibacterial activity of peptides. The ability of the linear
peptides and HNP-1 to kill both gram-positive and gram-neg-
ative bacteria was investigated. The lethal concentrations for
killing E. coli, P. aeruginosa, and S. aureus are shown in Table
2. The results indicate that HNP-1 analogs which lack cys-
teines, and hence the disulfide cross-links, can still display
significant antibacterial activity. However, HNP-1 exhibited
greater activity than the analogs. The deletion of AYRIPA
from HNP-1	C resulted in the attenuation of antibacterial
activity. The replacement of G by A in HNP-1	C18 marginally
increased the potency against E. coli.
Bacterial killing (reduction in log10 CFU/ml) as a function of
time at the LC is shown in Fig. 1. HNP-1	C killed E. coli, S.
aureus, and P. aeruginosa more rapidly than HNP-1. The
shorter analogs also killed E. coli and S. aureus more rapidly
than HNP-1. However, the rates of killing of P. aeruginosa by
the 18-residue peptides and HNP-1 were comparable. Rapid
killing of S. aureus by HNP-1	C18A compared to that by the
other peptides was observed.
Effect of salt and serum on antimicrobial activity. The ef-
fects of NaCl on the activities of HNP-1 and its analogs are
summarized in Table 3. The activity of HNP-1	C was margin-
ally lower against E. coli and S. aureus but decreased consid-
erably against P. aeruginosa. The shorter peptides exhibited
relatively greater losses in activity against E. coli. When G was
replaced by A in HNP-1	C18, the loss in activity against P.
aeruginosa and S. aureus was relatively less.
When the effects of divalent cations on HNP-1 and its ana-
logs were examined, there was a complete loss of antibacterial
activity in the presence of 1 mM MgCl2 for the analogs, unlike
TABLE 1. Primary structure of HNP-1 and its analogs
Peptide Sequence
HNP-1............................................
HNP-1	C ......................................
HNP-1	C18 ..................................
HNP-1	C18A ...............................
TABLE 2. Antibacterial activity of peptides
Bacterium
Lethal concentration (M)a of peptide
HNP-1 HNP-1	C HNP-1	C18 HNP-1	C18A
E. coli W 160-37 1.0  0.2 14.0  2.0 19.0  3.0 14.0  2.0
P. aeruginosa
NCTC 6750
1.0  0.2 14.0  2.0 23.0  3.0 23.0  3.0
S. aureus NCTC
8530
0.8  0.2 7.0  2.0 10.0  2.0 9.0  2.0
a The values reported for the analogs are means  maximum variations ob-
served in three independent experiments.
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HNP-1, which was active even in the presence of 2 mM MgCl2
(data not shown). However, the presence of 2 mM CaCl2
seemed to have only a marginal effect on the antibacterial
activity of the three linear analogs toward E. coli MG1655. A
complete loss in the activity of HNP-1 was observed in the
presence of Ca2 (data not shown), as reported earlier (20).
Both Mg2 and Ca2 bind to lipopolysaccharides and stabilize
the outer membrane of E. coli (45). Our results suggest that
there could be differences in affinity between the linear analogs
and HNP-1 for lipopolysaccharides.
The antibacterial activities of the 18-residue peptides were
not affected in the presence of serum (Table 3, values in pa-
rentheses). HNP-1 and HNP-1	C showed reduced activities
against E. coli. While HNP-1 was rendered inactive against P.
aeruginosa and S. aureus, HNP-1	C showed a considerably
reduced activity (Table 3).
Outer and inner membrane permeabilization assays. De-
fensins are known to act by sequentially permeabilizing the
outer and inner membranes of E. coli (20). NPN, a neutral
hydrophobic probe, has been used to examine the permeabi-
lization of the outer membranes of gram-negative bacteria
(38). All of the analogs permeabilized the outer membrane of
E. coli in a concentration-dependent manner, as observed by
an increase in NPN fluorescence (Fig. 2), despite differences in
the inhibition of antibacterial activity by Mg2 and Ca2 be-
tween HNP-1 and the linear analogs.
When the ability of the peptides to permeabilize the inner
membrane of E. coli was examined by the ONPG assay (21), no
influx of ONPG was observed, suggesting that the peptides do
not permeabilize the inner membrane (data not shown), unlike
HNP-1, which was effective in permeabilizing the inner mem-
brane.
Effect of dissipation of proton motive force on antibacterial
activity. The effect of depolarizing the bacterial inner mem-
brane with CCCP on the antibacterial activity of the peptides
was examined. HNP-1 and its analogs exhibited bactericidal
activities against E. coli, P. aeruginosa, and S. aureus at their
LCs in the absence of a proton motive force as a result of
adding 20 M CCCP. Similar results were observed when 50
M CCCP was used (data not shown). The peptides were
effective against P. aeruginosa in the absence of a proton mo-
tive force, even in the presence of 100 mM NaCl (data not
shown).
Lysis of human erythrocytes. The ability of the peptides to
lyse human red blood cells is shown in Table 4. For comparable
concentrations of peptides, maximum hemolysis was observed
with HNP-1	C18A, which was, however, neutralized in the
presence of human serum.
Conformation of peptides. Circular dichroism (CD) spec-
troscopy was carried out for all three peptides in water, undi-
luted TFE, and 10 mM SDS (Fig. 3). The spectra of the
peptides in water are characteristic of unordered conforma-
tions. The spectra of HNP1	C in TFE and SDS suggest a
population with a -hairpin conformation (4, 6, 18) character-
ized by a negative ellipticity near 205 nm and a crossover at

200 nm. In TFE, both the HNP-1	C18 and HNP-1	C18A
spectra display minima at 
205 nm and 
223 nm, with a
crossover at 
200 nm. The spectra indicate the presence of
populations with both -hairpin and helical conformations (4,
6, 18). In 10 mM SDS, HNP-1	C18A shows a minimum at
TABLE 3. Effect of NaCl and human serum on antibacterial
activity of peptides
Bacterium
% Bacterial killing in presence of NaCl
(in presence of human serum)a
HNP-1 HNP-1	C HNP-1	C18 HNP-1	C18A
E. coli W 160-37 68 (50) 81 (47) 68 (100) 59 (100)
P. aeruginosa NCTC 6750 45 (0) 10 (13) 12 (87) 41 (98)
S. aureus NCTC 8530 33 (0) 92 (24) 63 (99) 84 (99)
a Mid-log-phase bacteria (105 CFU/ml) were incubated with the LCs of pep-
tides in the presence of 100 mM NaCl. The values in parentheses correspond to
the effect of human serum on antibacterial activity in the absence of NaCl.
Peptides were used at their LCs and were added after 15 minutes of incubation
with 1 mg/ml of serum. The values reported are the averages of three indepen-
dent experiments. The variation was within 5%.
FIG. 1. Kinetics of bacterial killing. Symbols: }, HNP-1; F, HNP-
1	C; ■, HNP-1	C18; and Œ, HNP-1	C18A. Mid-log-phase bacteria
(105 CFU/ml) were incubated with peptides at their lethal concentra-
tions.
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214 nm and a crossover at 
200 nm, which may indicate a
population largely consisting of a -structure.
DISCUSSION
In this study, we have examined the antibacterial activities of
linear peptides derived from the HNP-1 sequence without cys-
teines. The linear analogs of HNP-1 do possess antibacterial
activity, although their lethal concentrations are approximately
10- to 20-fold higher than that of HNP-1.
The antibacterial activities exhibited by HNP-1	C18 and
HNP-1	C18A suggest that the six N-terminal amino acids
AYRIPA present in HNP-1 are dispensable for activity, even
in the context of the linear sequence. It was shown earlier that
peptides derived from the HNP-1 sequence without AYRIPA,
but constrained by one or two disulfide bridges, have antibac-
terial activity (28). The residue G does not appear to play a
crucial structural role, as its replacement with A does not
diminish the activity. CD data indicate that linear HNP-1	C
does tend to adopt a -structure, suggesting that there is an
intrinsic propensity of the peptide sequence to adopt this con-
formation rather than its being due to constraints imposed by
disulfide bridges. When G is replaced with A, the peptide
favors a helical conformation. This observation suggests that
the positioning of cationic and hydrophobic residues in
-strands in HNP-1 is not the only structural feature that is
essential for the exhibition of antibacterial activity.
We have observed that the activity of HNP-1 is not com-
pletely abolished in the presence of 100 mM NaCl, although
there have been reports that the antibacterial activity of HNP-1
is completely lost in the presence of high salt concentrations
(31, 44). It is conceivable that a loss in activity in the presence
of NaCl may depend on the assay employed. A loss of anti-
bacterial activity in the presence of a high salt concentration
has been observed for HNP-1 in the radial diffusion assay,
which has been extensively used to determine the antibacterial
activities of mammalian defensins (44, 56). Also, the inhibition
of antibacterial activity by human neutrophil defensins appears
to be strain dependent (12, 44). Like HNP-1, all of the linear
peptides permeabilize the outer membrane of E. coli. Subse-
quently, the linear peptides do not permeabilize the inner
membrane to cause an influx of ONPG, as observed with
HNP-1 (20, 21). However, it is likely that the site of action is
the inner membrane, considering the rapid rate of killing. The
FIG. 2. Outer membrane permeabilization of E. coli MG 1655 by HNP-1 and its analogs. (A) HNP-1	C; (B) HNP-1	C18; (C) HNP-1	C18A;
(D) HNP-1. Permeabilization of the outer membrane was monitored as an increase in NPN fluorescence intensity in the presence of various
concentrations of peptides, as indicated adjacent to the traces.
TABLE 4. Hemolytic activity of peptides
Concn of peptide
(M)
% Hemolysis by peptidea
HNP-1 HNP-1	C HNP-1	C18 HNP-1	C18A
20 15 20 9 21
40 20 36 14 63
a Erythrocytes (107 cells/ml) were incubated with peptides in 5 mM HEPES
(pH 7.4) containing 150 mM NaCl. The values reported are the averages of three
independent experiments. The variation was within 5%.
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linear analogs and HNP-1 are active even in the presence of
CCCP. Since CCCP would discharge the pH gradient and
destroy the proton motive force across the inner membrane, it
appears that HNP-1 and the linear analogs can exert their
antibacterial activity even in the absence of a proton motive
force. It has been observed that the susceptibility of Neisseria
gonorrhoeae to the human defensin HNP-2 is not abolished in
the presence of CCCP (40). The bactericidal activity of HNP-1
against S. aureus is also not dependent on the transcytoplasmic
membrane electrical potential (52). Also, the loss of activity
against P. aeruginosa in the presence of 100 mM NaCl is not
observed when CCCP is present. The concentration of cyto-
plasmic Na is maintained by a Na-proton antiporter driven
by the proton motive force (10). CCCP inhibits the antiporter
function (10, 33). In the presence of a high NaCl concentration
in the external medium, the membrane potential does not
favor associations of the peptides with the membrane of P.
aeruginosa. However, when the membrane potential is dissi-
pated by the addition of CCCP, the high salt concentration is
no longer inhibitory. The linear peptides appear to exert their
antibacterial activity in the same way as polymyxin B (8). As in
the case of polymyxin B (8), the antibacterial activity of the
linear peptides is inhibited by Mg2. Tam and coworkers have
engineered a salt-insensitive rabbit -defensin with end-to-end
cyclization (56). They have speculated that the clustering of
cationic charges as a result of cyclization may promote salt
insensitivity. In the absence of disulfide constraints, it is un-
likely that a similar clustering of charges occurs in HNP-1	C.
Hence, the linearization of defensin may be a good strategy to
generate salt-insensitive antibacterial peptides.
The hemolytic assay indicates a reduction in hemolysis of
human erythrocytes with the analog HNP-1	C18 and an in-
crease with HNP-1	C18A. This may be due to decreased hy-
drophobicity in the case of HNP-1	C18 and a comparatively
increased helicity as well as hydrophobicity for HNP-1	C18A,
as observed for linear host defense antibacterial peptides (30,
37, 41). Earlier studies have shown that the microbicidal activ-
ity of HNPs is affected by the presence of serum (7, 55). We
have also observed that serum inhibits the antibacterial activity
of HNP-1. The HNP-1 analogs, particularly the truncated ones,
show bactericidal activity even in the presence of human se-
rum.
In summary, our studies have provided new insights into the
structure-function relationship of HNP-1. While it has been
demonstrated that all three disulfides or the order of connec-
tivity is not an essential feature for activity in defensins (27, 29,
49), our results indicate that linear peptides without cysteines
can still possess antibacterial activity, although it is 10- to
20-fold lower than that of HNP-1. The antibacterial activity is
only marginally inhibited by high concentrations of NaCl, es-
pecially against E. coli and S. aureus. The peptides are active
even in the absence of a proton motive force. The generation
of linear defensins would be easier than that of disulfide-linked
defensins, although defensins have been generated by chemical
synthesis and recombination methods (6, 9, 17, 27–29, 36, 49–
51, 56). Hence, linear defensins could have potential for de-
velopment as therapeutic agents.
ACKNOWLEDGMENT
We thank M. V. Jagannadham, Centre for Cellular and Molecular
Biology, Hyderabad, India, for help with mass spectral analysis.
REFERENCES
1. Atherton, E., and R. C. Sheppard. 1989. Solid phase peptide synthesis: a
practical approach. IRL Press, Oxford, United Kingdom.
2. Bals, R. 2000. Epithelial antimicrobial peptides in host defense against in-
fection. Respir. Res. 1:141–150.
3. Befus, A. D., C. Mowat, M. Gilchrist, J. Hu, S. Solomon, and A. Bateman.
1999. Neutrophil defensins induce histamine secretion from mast cells:
mechanisms of action. J. Immunol. 163:947–953.
4. Blanco, F. J., and L. Serrano. 1995. Folding of protein G B1 domain studied
by the conformational characterization of fragments comprising its second-
ary structure elements. Eur. J. Biochem. 230:634–649.
5. Chertov, O., D. F. Michiel, L. Xu, J. M. Wang, K. Tani, W. J. Murphy, D. L.
Longo, D. D. Taub, and J. J. Oppenheim. 1996. Identification of defensin-1,
defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins re-
leased from interleukin-8-stimulated neutrophils. J. Biol. Chem. 271:2935–
2940.
6. Circo, R., B. Skerlavaj, R. Gennaro, A. Amoroso, and M. Zanetti. 2002.
Structural and functional characterization of hBD-1(Ser35), a peptide de-
duced from a DEFB1 polymorphism. Biochem. Biophys. Res. Commun.
293:586–592.
7. Daher, K. A., M. E. Selsted, and R. I. Lehrer. 1986. Direct inactivation of
viruses by human granulocyte defensins. J. Virol. 60:1068–1074.
FIG. 3. CD spectra of HNP-1 analogs. CD spectra were measured
in water (}), TFE (■), and SDS (Œ).
VOL. 49, 2005 ANTIBACTERIAL ACTIVITY OF HNP-1 ANALOGS 4565
8. Daugelavicius, R., E. Bakiene, and D. H. Bamford. 2000. Stages of polymyxin
B interaction with the Escherichia coli cell envelope. Antimicrob. Agents
Chemother. 44:2969–2978.
9. Dawson, N. F., D. J. Craik, A. M. McManus, S. G. Dashper, E. C. Reynolds,
G. W. Tregear, L. Otvos, Jr., and J. D. Wade. 2000. Chemical synthesis,
characterization and activity of RK-1, a novel alpha-defensin-related pep-
tide. J. Pept. Sci. 6:19–25.
10. Dibrov, P. A. 1991. The role of sodium ion transport in Escherichia coli
energetics. Biochim. Biophys. Acta 1056:209–224.
11. Durr, M., and A. Peschel. 2002. Chemokines meet defensins: the emerging
concepts of chemoattractants and antimicrobial peptides in host defense.
Infect. Immun. 70:6515–6517.
12. Ericksen, B., Z. Wu, W. Lu, and R. I. Lehrer. 2005. Antibacterial activity and
specificity of the six human -defensins. Antimicrob. Agents Chemother.
49:269–275.
13. Ganz, T. 2003. Defensins: antimicrobial peptides of innate immunity. Nat.
Rev. Immunol. 3:710–720.
14. Gudmundsson, G. H., and B. Agerberth. 1999. Neutrophil antibacterial pep-
tides, multifunctional effector molecules in the mammalian immune system.
J. Immunol. Methods 232:45–54.
15. Gullberg, U., N. Bengtsson, E. Bulow, D. Garwicz, A. Lindmark, and I.
Olsson. 1999. Processing and targeting of granule proteins in human neu-
trophils. J. Immunol. Methods 232:201–210.
16. Hill, C. P., J. Yee, M. E. Selsted, and D. Eisenberg. 1991. Crystal structure of
defensin HNP-3, an amphiphilic dimer: mechanisms of membrane perme-
abilization. Science 251:1481–1485.
17. Hoover, D. M., Z. Wu, K. Tucker, W. Lu, and J. Lubkowski. 2003. Antimi-
crobial characterization of human beta-defensin 3 derivatives. Antimicrob.
Agents Chemother. 47:2804–2809.
18. Krishnakumari, V., A. Sharadadevi, S. Singh, and R. Nagaraj. 2003. Single
disulfide and linear analogues corresponding to the carboxy-terminal seg-
ment of bovine beta-defensin-2: effects of introducing the beta-hairpin nu-
cleating sequence D-Pro-Gly on antibacterial activity and biophysical prop-
erties. Biochemistry 42:9307–9315.
19. Lehrer, R. I. 2004. Primate defensins. Nat. Rev. Microbiol. 2:727–738.
20. Lehrer, R. I., A. Barton, K. A. Daher, S. S. Harwig, T. Ganz, and M. E.
Selsted. 1989. Interaction of human defensins with Escherichia coli. Mech-
anism of bactericidal activity. J. Clin. Investig. 84:553–561.
21. Lehrer, R. I., A. Barton, and T. Ganz. 1988. Concurrent assessment of inner
and outer membrane permeabilization and bacteriolysis in E. coli by multi-
ple-wavelength spectrophotometry. J. Immunol. Methods 108:153–158.
22. Lehrer, R. I., and T. Ganz. 2002. Defensins of vertebrate animals. Curr.
Opin. Immunol. 14:96–102.
23. Lehrer, R. I., A. K. Lichtenstein, and T. Ganz. 1993. Defensins: antimicrobial
and cytotoxic peptides of mammalian cells. Annu. Rev. Immunol. 11:105–
128.
24. Lillard, J. W., Jr., P. N. Boyaka, O. Chertov, J. J. Oppenheim, and J. R.
McGhee. 1999. Mechanisms for induction of acquired host immunity by
neutrophil peptide defensins. Proc. Natl. Acad. Sci. USA 96:651–656.
25. Loh, B., C. Grant, and R. E. Hancock. 1984. Use of the fluorescent probe
1-N-phenylnaphthylamine to study the interactions of aminoglycoside anti-
biotics with the outer membrane of Pseudomonas aeruginosa. Antimicrob.
Agents Chemother. 26:546–551.
26. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein
measurement with the Folin phenol reagent. J. Biol. Chem. 193:265–275.
27. Maemoto, A., X. Qu, K. J. Rosengren, H. Tanabe, A. Henschen-Edman, D. J.
Craik, and A. J. Ouellette. 2004. Functional analysis of the alpha-defensin
disulfide array in mouse cryptdin-4. J. Biol. Chem. 279:44188–44196.
28. Mandal, M., and R. Nagaraj. 2002. Antibacterial activities and conforma-
tions of synthetic alpha-defensin HNP-1 and analogs with one, two and three
disulfide bridges. J. Pept. Res. 59:95–104.
29. Mandal, M., M. V. Jagannadham, and R. Nagaraj. 2002. Antibacterial ac-
tivities and conformations of bovine beta-defensin BNBD-12 and analogs:
structural and disulfide bridge requirements for activity. Peptides 23:413–
418.
30. Matsuzaki, K. 1998. Magainins as paradigm for the mode of action of pore
forming polypeptides. Biochim. Biophys. Acta 1376:391–400.
31. Nagaoka, I., S. Hirota, S. Yomogida, A. Ohwada, and M. Hirata. 2000.
Synergistic actions of antibacterial neutrophil defensins and cathelicidins.
Inflamm. Res. 49:73–79.
32. Niyonsaba, F., H. Ogawa, and I. Nagaoka. 2004. Human beta-defensin-2
functions as a chemotactic agent for tumour necrosis factor-alpha-treated
human neutrophils. Immunology 111:273–281.
33. Ohyama, T., S. Mugikura, M. Nishikawa, K. Igarashi, and H. Kobayashi.
1992. Osmotic adaptation of Escherichia coli with a negligible proton motive
force in the presence of carbonyl cyanide m-chlorophenylhydrazone. J. Bac-
teriol. 174:2922–2928.
34. Pardi, A., X. L. Zhang, M. E. Selsted, J. J. Skalicky, and P. F. Yip. 1992.
NMR studies of defensin antimicrobial peptides. 2. Three-dimensional struc-
tures of rabbit NP-2 and human HNP-1. Biochemistry 31:11357–11364.
35. Raj, P. A., and A. R. Dentino. 2002. Current status of defensins and their role
in innate and adaptive immunity. FEMS Microbiol. Lett. 206:9–18.
36. Rao, A. G., T. Rood, J. Maddox, and J. Duvick. 1992. Synthesis and charac-
terization of defensin NP-1. Int. J. Pept. Protein Res. 40:507–514.
37. Saberwal, G., and R. Nagaraj. 1994. Cell-lytic and antibacterial peptides that
act by perturbing the barrier function of membranes: facets of their confor-
mational features, structure-function correlations and membrane-perturbing
abilities. Biochim. Biophys. Acta 1197:109–131.
38. Sedgwick, E. G., and P. D. Bragg. 1987. Distinct phases of the fluorescence
response of the lipophilic probe N-phenyl-1-naphthylamine in intact cells
and membrane vesicles of Escherichia coli. Biochim. Biophys. Acta 894:499–
506.
39. Selsted, M. E., and A. J. Ouellette. 1995. Defensins in granules of phagocytic
and non-phagocytic cells. Trends Cell Biol. 5:114–119.
40. Shafer, W. M., X. D. Qu, A. J. Waring, and R. I. Lehrer. 1998. Modulation
of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides
due to a member of the resistance/nodulation/division efflux pump family.
Proc. Natl. Acad. Sci. USA 95:1829–1833.
41. Sitaram, N., and R. Nagaraj. 1999. Interaction of antimicrobial peptides with
biological and model membranes: structural and charge requirements for
activity. Biochim. Biophys. Acta 1462:29–54.
42. Tam, J. P., C. R. Wu, W. Liu, and J. W. Zhang. 1991. Disulfide bond
formation in peptides by dimethyl sulfoxide. Scope and applications. J. Am.
Chem. Soc. 113:6657–6662.
43. Territo, M. C., T. Ganz, M. E. Selsted, and R. Lehrer. 1989. Monocyte-
chemotactic activity of defensins from human neutrophils. J. Clin. Investig.
84:2017–2020.
44. Turner, J., Y. Cho, N. N. Dinh, A. J. Waring, and R. I. Lehrer. 1998.
Activities of LL-37, a cathelin-associated antimicrobial peptide of human
neutrophils. Antimicrob. Agents Chemother. 42:2206–2214.
45. Vaara, M. 1992. Agents that increase the permeability of the outer mem-
brane. Microbiol. Rev. 56:395–411.
46. Veber, D. F., J. D. Milkowski, S. L. Varga, R. G. Denkewalter, and R.
Hirschmann. 1972. Acetamidomethyl. A novel thiol protecting group for
cysteine. J. Am. Chem. Soc. 94:5456–5461.
47. Vogel, H. J. 1953. Path of ornithine synthesis in Escherichia coli. Proc. Natl.
Acad. Sci. USA 39:578–583.
48. Welling, M. M., P. S. Hiemstra, M. T. van den Barselaar, A. Paulusma-
Annema, P. H. Nibbering, E. K. Pauwels, and W. Calame. 1998. Antibacte-
rial activity of human neutrophil defensins in experimental infections in mice
is accompanied by increased leukocyte accumulation. J. Clin. Investig. 102:
1583–1590.
49. Wu, Z., D. M. Hoover, D. Yang, C. Boulegue, F. Santamaria, J. J. Oppen-
heim, J. Lubkowski, and W. Lu. 2003. Engineering disulfide bridges to
dissect antimicrobial and chemotactic activities of human beta-defensin 3.
Proc. Natl. Acad. Sci. USA 100:8880–8885.
50. Wu, Z., B. Ericksen, K. Tucker, J. Lubkowski, and W. Lu. 2004 Synthesis and
characterization of human alpha-defensins 4–6. J. Pept. Res. 64:118–125.
51. Wu, Z., A. Prahl, R. Powell, B. Ericksen, J. Lubkowski, and W. Lu. 2003.
From pro defensins to defensins: synthesis and characterization of human
neutrophil pro alpha-defensin-1 and its mature domain. J. Pept. Res. 62:53–
62.
52. Xiong, Y. Q., M. R. Yeaman, and A. S. Bayer. 1999. In vitro antibacterial
activities of platelet microbicidal protein and neutrophil defensin against
Staphylococcus aureus are influenced by antibiotics differing in mechanism of
action. Antimicrob. Agents Chemother. 43:1111–1117.
53. Yang, D., A. Biragyn, L. W. Kwak, and J. J. Oppenheim. 2002. Mammalian
defensins in immunity: more than just microbicidal. Trends Immunol. 23:
291–296.
54. Yang, D., Q. Chen, O. Chertov, and J. J. Oppenheim. 2000. Human neutro-
phil defensins selectively chemoattract naive T and immature dendritic cells.
J. Leukoc. Biol. 68:9–14.
55. Yasin, B., S. S. Harwig, R. I. Lehrer, and E. A. Wagar. 1996. Susceptibility of
Chlamydia trachomatis to protegrins and defensins. Infect. Immun. 64:709–
713.
56. Yu, Q., R. I. Lehrer, and J. P. Tam. 2000. Engineered salt-insensitive alpha-
defensins with end-to-end circularized structures. J. Biol. Chem. 275:3943–
3949.
57. Zhang, X. L., M. E. Selsted, and A. Pardi. 1992. NMR studies of defensin
antimicrobial peptides. 1. Resonance assignment and secondary structure
determination of rabbit NP-2 and human HNP-1. Biochemistry 31:11348–
11356.
4566 VARKEY AND NAGARAJ ANTIMICROB. AGENTS CHEMOTHER.
